Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Scand J Gastroenterol

Retrieve available abstracts of 145 articles:
HTML format
Text format



Single Articles


    May 2018
  1. YADAV A, Foromera J, Falchuk KR, Feuerstein JD, et al
    Biologics and immunomodulators for treating Crohn's disease developing after surgery for an initial diagnosis of ulcerative colitis: a review of current literature.
    Scand J Gastroenterol. 2018 May 2:1-5. doi: 10.1080/00365521.2018.1468478.
    PubMed     Text format     Abstract available


    April 2018
  2. YERUSHALMY-FELER A, Ben-Tov A, Weintraub Y, Amir A, et al
    High and low body mass index may predict severe disease course in children with inflammatory bowel disease.
    Scand J Gastroenterol. 2018 Apr 24:1-6. doi: 10.1080/00365521.2018.1464595.
    PubMed     Text format     Abstract available


  3. RATNAKUMARAN R, To N, Gracie DJ, Selinger CP, et al
    Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience.
    Scand J Gastroenterol. 2018 Apr 24:1-8. doi: 10.1080/00365521.2018.1464203.
    PubMed     Text format     Abstract available


    March 2018
  4. KEIL R, Wasserbauer M, Zadorova Z, Kojecky V, et al
    Adherence, risk factors of non-adherence and patient's preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study.
    Scand J Gastroenterol. 2018 Mar 21:1-7. doi: 10.1080/00365521.2018.1451915.
    PubMed     Text format     Abstract available


  5. WICKBOM A, Bohr J, Nyhlin N, Eriksson A, et al
    Microscopic colitis in patients with ulcerative colitis or Crohn's disease: a retrospective observational study and review of the literature.
    Scand J Gastroenterol. 2018 Mar 16:1-7. doi: 10.1080/00365521.2018.1430252.
    PubMed     Text format     Abstract available


  6. AHLUWALIA B, Moraes L, Magnusson MK, Ohman L, et al
    Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies.
    Scand J Gastroenterol. 2018 Mar 9:1-11. doi: 10.1080/00365521.2018.1447597.
    PubMed     Text format     Abstract available


  7. DIGNASS A, Akbar A, Baumgart DC, Bommelaer G, et al
    Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis.
    Scand J Gastroenterol. 2018 Mar 7:1-7. doi: 10.1080/00365521.2018.1447598.
    PubMed     Text format     Abstract available


  8. ZAGOROWICZ E, Przybysz A, Szlak J, Magdziak A, et al
    Detection of cytomegalovirus by immunohistochemistry of colonic biopsies and quantitative blood polymerase chain reaction: evaluation of agreement in ulcerative colitis.
    Scand J Gastroenterol. 2018 Mar 7:1-7. doi: 10.1080/00365521.2018.1447596.
    PubMed     Text format     Abstract available


    February 2018
  9. KANGASPUNTA M, Haapamaki J, Farkkila M, Arkkila P, et al
    Inflammatory bowel disease and anemia: intravenous iron treatment.
    Scand J Gastroenterol. 2018 Feb 22:1-5. doi: 10.1080/00365521.2018.1441435.
    PubMed     Text format     Abstract available


  10. GREENSTEIN RJ, Brown ST
    A data-based hypothesis explicating the observations that "Smoking is associated with risk for developing inflammatory bowel disease including late onset ulcerative colitis: a prospective study".
    Scand J Gastroenterol. 2018 Feb 15:1. doi: 10.1080/00365521.2018.1440003.
    PubMed     Text format    


    January 2018
  11. MOORE C
    Response to "Clinical implications of assay-specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time".
    Scand J Gastroenterol. 2018 Jan 31:1. doi: 10.1080/00365521.2018.1428400.
    PubMed     Text format    


  12. KLEPP P, Kisiel JB, Smastuen MC, Roseth A, et al
    Multi-target stool DNA test in the surveillance of inflammatory bowel disease: a cross-sectional cohort study.
    Scand J Gastroenterol. 2018 Jan 9:1-6. doi: 10.1080/00365521.2018.1424935.
    PubMed     Text format     Abstract available


    December 2017
  13. SALIH A, Widbom L, Hultdin J, Karling P, et al
    Smoking is associated with risk for developing inflammatory bowel disease including late onset ulcerative colitis: a prospective study.
    Scand J Gastroenterol. 2017 Dec 21:1-6. doi: 10.1080/00365521.2017.1418904.
    PubMed     Text format     Abstract available


  14. YLISAUKKO-OJA T, Aaltonen J, Nuutinen H, Blomster T, et al
    High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)().
    Scand J Gastroenterol. 2017 Dec 19:1-10. doi: 10.1080/00365521.2017.1416160.
    PubMed     Text format     Abstract available


  15. RIBALDONE DG, Vernero M, Saracco GM, Pellicano R, et al
    The adherence to the therapy in inflammatory bowel disease: beyond the number of the tablets.
    Scand J Gastroenterol. 2017 Dec 11:1-6. doi: 10.1080/00365521.2017.1405070.
    PubMed     Text format     Abstract available


  16. LIMKETKAI BN, Sepulveda R, Hing T, Shah ND, et al
    Prevalence and factors associated with gluten sensitivity in inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Dec 7:1-5. doi: 10.1080/00365521.2017.1409364.
    PubMed     Text format     Abstract available


    November 2017
  17. GARCIA-PLANELLA E, Manosa M, Chaparro M, Beltran B, et al
    Serial semi-quantitative measurement of fecal calprotectin in patients with ulcerative colitis in remission.
    Scand J Gastroenterol. 2017 Nov 30:1-6. doi: 10.1080/00365521.2017.1410219.
    PubMed     Text format     Abstract available


  18. NISHIDA Y, Hosomi S, Watanabe K, Watanabe K, et al
    Serum interleukin-6 level is associated with response to infliximab in ulcerative colitis.
    Scand J Gastroenterol. 2017 Nov 24:1-7. doi: 10.1080/00365521.2017.1403647.
    PubMed     Text format     Abstract available


  19. BAGER P, Chauhan U, Greveson K, Jaghult S, et al
    Systematic review: advice lines for patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Nov 13:1-7. doi: 10.1080/00365521.2017.1401116.
    PubMed     Text format     Abstract available


    October 2017
  20. THEOCHARI NA, Stefanopoulos A, Mylonas KS, Economopoulos KP, et al
    Antibiotics exposure and risk of inflammatory bowel disease: a systematic review.
    Scand J Gastroenterol. 2017 Oct 12:1-7. doi: 10.1080/00365521.2017.1386711.
    PubMed     Text format     Abstract available



  21. Correction to: Carvalho et al., Prevalence of iron deficiency anemia and iron deficiency in a pediatric population with inflammatory bowel disease.
    Scand J Gastroenterol. 2017;52:ii.
    PubMed     Text format    


    September 2017
  22. KRIDIN K, Zelber-Sagi S, Comaneshter D, Cohen AD, et al
    Ulcerative colitis associated with pemphigus: a population-based large-scale study.
    Scand J Gastroenterol. 2017 Sep 28:1-5. doi: 10.1080/00365521.2017.1380839.
    PubMed     Text format     Abstract available


    August 2017
  23. EBERL A, Huoponen S, Pahikkala T, Blom M, et al
    Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
    Scand J Gastroenterol. 2017 Aug 24:1-6. doi: 10.1080/00365521.2017.1369561.
    PubMed     Text format     Abstract available


  24. SAFFOURI G, Gupta A, Loftus EV Jr, Baddour LM, et al
    The incidence and outcomes from Clostridium difficile infection in hospitalized adults with inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Aug 6:1-8. doi: 10.1080/00365521.2017.1362466.
    PubMed     Text format     Abstract available


    July 2017
  25. KHAJAH MA
    The potential role of fecal microbiota transplantation in the treatment of inflammatory Bowel disease.
    Scand J Gastroenterol. 2017 Jul 7:1-13. doi: 10.1080/00365521.2017.1347812.
    PubMed     Text format     Abstract available


    June 2017
  26. SMIDS C, Horjus Talabur Horje CS, Groenen MJM, van Koolwijk EHM, et al
    The value of serum antibodies in differentiating inflammatory bowel disease, predicting disease activity and disease course in the newly diagnosed patient.
    Scand J Gastroenterol. 2017 Jun 29:1-9. doi: 10.1080/00365521.2017.1344875.
    PubMed     Text format     Abstract available


  27. CARVALHO FSG, de Medeiros IA, Antunes H
    Prevalence of iron deficiency anemia and iron deficiency in a pediatric population with inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Jun 23:1-5. doi: 10.1080/00365521.2017.1342137.
    PubMed     Text format     Abstract available



  28. Correction to: Kokkinidis DG, et al. Emerging treatments for ulcerative colitis: a systematic review.
    Scand J Gastroenterol. 2017 Jun 23:1. doi: 10.1080/00365521.2017.1341083.
    PubMed     Text format    


  29. ABOLFOTOUH S, Rautio T, Klintrup K, Helavirta I, et al
    Predictors of quality-of-life after ileal pouch-anal anastomosis in patients with ulcerative colitis.
    Scand J Gastroenterol. 2017 Jun 9:1-8. doi: 10.1080/00365521.2017.1337218.
    PubMed     Text format     Abstract available


  30. CON D, Jackson B, Gray K, De Cruz P, et al
    eHealth for inflammatory bowel disease self-management - the patient perspective.
    Scand J Gastroenterol. 2017 Jun 9:1-8. doi: 10.1080/00365521.2017.1333625.
    PubMed     Text format     Abstract available


  31. ROTHSCHILD B, Rinawi F, Herman Y, Nir O, et al
    Prognostic significance of granulomas in children with Crohn's disease.
    Scand J Gastroenterol. 2017;52.
    PubMed     Text format     Abstract available


  32. CARDILE S, Alterio T, Candusso M, Pietrobattista A, et al
    Autoimmune liver diseases and inflammatory bowel diseases in children: current issues and future perspectives.
    Scand J Gastroenterol. 2017;52.
    PubMed     Text format     Abstract available


    May 2017
  33. MACALUSO FS, Renna S, Maida M, Dimarco M, et al
    Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience.
    Scand J Gastroenterol. 2017 May 29:1-7. doi: 10.1080/00365521.2017.1333626.
    PubMed     Text format     Abstract available


  34. JACKSON B, Con D, Ma R, Gorelik A, et al
    Health care costs associated with Australian tertiary inflammatory bowel disease care.
    Scand J Gastroenterol. 2017 May 16:1-6. doi: 10.1080/00365521.2017.1323117.
    PubMed     Text format     Abstract available


  35. KOKKINIDIS DG, Bosdelekidou EE, Iliopoulou SM, Tassos AG, et al
    Emerging treatments for ulcerative colitis: a systematic review.
    Scand J Gastroenterol. 2017 May 14:1-9. doi: 10.1080/00365521.2017.1326163.
    PubMed     Text format     Abstract available


  36. SEO H, Chang K, Lee SH, Song EM, et al
    Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea.
    Scand J Gastroenterol. 2017 May 14:1-7. doi: 10.1080/00365521.2017.1323229.
    PubMed     Text format     Abstract available


  37. MARTELLI L, Colard A, Fontaine F, Deflandre J, et al
    Evaluation of the efficacy of octreotide LAR in the treatment of Crohn's disease associated refractory diarrhea.
    Scand J Gastroenterol. 2017;52:564-569.
    PubMed     Text format     Abstract available


  38. SASIDHARAN S, Yajnik V, Khalili H, Garber J, et al
    Genetic risk factors for serious infections in inflammatory bowel diseases.
    Scand J Gastroenterol. 2017;52:570-576.
    PubMed     Text format     Abstract available


  39. VARMA P, Falconer J, Aga A, Prince HM, et al
    Rituximab-induced Crohn's disease.
    Scand J Gastroenterol. 2017;52:606-608.
    PubMed     Text format     Abstract available


  40. RINAWI F, Assa A, Eliakim R, Mozer-Glassberg Y, et al
    The natural history of pediatric-onset IBD-unclassified and prediction of Crohn's disease reclassification: a 27-year study.
    Scand J Gastroenterol. 2017;52:558-563.
    PubMed     Text format     Abstract available


  41. RYSKA O, Serclova Z, Mestak O, Matouskova E, et al
    Local application of adipose-derived mesenchymal stem cells supports the healing of fistula: prospective randomised study on rat model of fistulising Crohn's disease.
    Scand J Gastroenterol. 2017;52:543-550.
    PubMed     Text format     Abstract available


    April 2017
  42. KWAPISZ L, Gregor J, Chande N, Yan B, et al
    The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Apr 20:1-5. doi: 10.1080/00365521.2017.1315740.
    PubMed     Text format     Abstract available


  43. LEE KE, Jung SA, Yoon H, Park SH, et al
    Factors associated with pregnancy-related knowledge in women of reproductive age with inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Apr 7:1-7. doi: 10.1080/00365521.2017.1310288.
    PubMed     Text format     Abstract available


    March 2017
  44. JAIME F, Riutort MC, Alvarez-Lobos M, Hoyos-Bachiloglu R, et al
    Solar radiation is inversely associated with inflammatory bowel disease admissions.
    Scand J Gastroenterol. 2017 Mar 31:1-8. doi: 10.1080/00365521.2017.1307444.
    PubMed     Text format     Abstract available


  45. ERIKSSON C, Marsal J, Bergemalm D, Vigren L, et al
    Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
    Scand J Gastroenterol. 2017 Mar 31:1-8. doi: 10.1080/00365521.2017.1304987.
    PubMed     Text format     Abstract available


  46. WLODARCZYK M, Sobolewska-Wlodarczyk A, Cygankiewicz AI, Jacenik D, et al
    G protein-coupled receptor 55 (GPR55) expresses differently in patients with Crohn's disease and ulcerative colitis.
    Scand J Gastroenterol. 2017 Mar 8:1-5. doi: 10.1080/00365521.2017.1298834.
    PubMed     Text format     Abstract available


  47. MURRAY IA, Murray LK, Woolson KL, Sherfi H, et al
    Incidence and predictive factors for positive 75SeHCAT test: improving the diagnosis of bile acid diarrhoea.
    Scand J Gastroenterol. 2017 Mar 5:1-6. doi: 10.1080/00365521.2017.1298153.
    PubMed     Text format     Abstract available


  48. MARTI-GALLOSTRA M, Myrelid P, Mortensen N, Keshav S, et al
    The role of a defunctioning stoma for colonic and perianal Crohn's disease in the biological era.
    Scand J Gastroenterol. 2017;52:251-256.
    PubMed     Text format     Abstract available


  49. BAR-GIL SHITRIT A, Koslowsky B, Livovsky DM, Shitrit D, et al
    A prospective study of fecal calprotectin and lactoferrin as predictors of small bowel Crohn's disease in patients undergoing capsule endoscopy.
    Scand J Gastroenterol. 2017;52:328-333.
    PubMed     Text format     Abstract available


    February 2017
  50. WALDUM HL, Bjornsson ES, Brenna E
    Chronic cholestatic liver diseases.
    Scand J Gastroenterol. 2017 Feb 28:1. doi: 10.1080/00365521.2017.1296276.
    PubMed     Text format    


  51. BOND A, Dodd S, Fisher G, Skouras T, et al
    Concurrent immunomodulator therapy is associated with higher adalimumab trough levels during scheduled maintenance therapy.
    Scand J Gastroenterol. 2017;52:204-208.
    PubMed     Text format     Abstract available


    January 2017
  52. YE X, Liu S, Hu M, Song Y, et al
    CCR5 expression in inflammatory bowel disease and its correlation with inflammatory cells and beta-arrestin2 expression.
    Scand J Gastroenterol. 2017 Jan 31:1-10. doi: 10.1080/00365521.2017.1281435.
    PubMed     Text format     Abstract available


  53. JACKSON BD, Con D, Liew D, De Cruz P, et al
    Clinicians' adherence to international guidelines in the clinical care of adults with inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Jan 27:1-7. doi: 10.1080/00365521.2017.1278785.
    PubMed     Text format     Abstract available


  54. LANDERHOLM K, Abdalla M, Myrelid P, Andersson RE, et al
    Survival of ileal pouch anal anastomosis constructed after colectomy or secondary to a previous ileorectal anastomosis in ulcerative colitis patients: a population-based cohort study.
    Scand J Gastroenterol. 2017 Jan 19:1-5. doi: 10.1080/00365521.2016.1278457.
    PubMed     Text format     Abstract available


  55. RONNBLOM A, Holmstrom T, Karlbom U, Tanghoj H, et al
    Clinical course of Crohn's disease during the first 5 years. Results from a population-based cohort in Sweden (ICURE) diagnosed 2005-2009.
    Scand J Gastroenterol. 2017;52:81-86.
    PubMed     Text format     Abstract available


  56. VALERIO DE AZEVEDO S, Maltez C, Lopes AI
    Pediatric Crohn's disease, iron deficiency anemia and intravenous iron treatment: a follow-up study.
    Scand J Gastroenterol. 2017;52:29-33.
    PubMed     Text format     Abstract available


  57. BEAUPEL N, Brouquet A, Abdalla S, Carbonnel F, et al
    Preoperative oral polymeric diet enriched with transforming growth factor-beta 2 (Modulen) could decrease postoperative morbidity after surgery for complicated ileocolonic Crohn's disease.
    Scand J Gastroenterol. 2017;52:5-10.
    PubMed     Text format     Abstract available


    December 2016
  58. GRIMSTAD T, Skoie IM, Doerner J, Isaksen K, et al
    TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease.
    Scand J Gastroenterol. 2016 Dec 31:1-5. doi: 10.1080/00365521.2016.1273382.
    PubMed     Text format     Abstract available


  59. CANCADO GG, Vilela EG
    Guillain-Barre syndrome during adalimumab therapy for Crohn s disease: coincidence or consequence?
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  60. LAURELL A, Sjoberg K
    Prebiotics and synbiotics in ulcerative colitis.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  61. BROMS G, Granath F, Stephansson O, Kieler H, et al
    Preterm birth in women with inflammatory bowel disease - the association with disease activity and drug treatment.
    Scand J Gastroenterol. 2016;51:1462-1469.
    PubMed     Text format     Abstract available


    November 2016
  62. OLBJORN C, Cvancarova Smastuen M, Thiis-Evensen E, Nakstad B, et al
    Serological markers in diagnosis of pediatric inflammatory bowel disease and as predictors for early tumor necrosis factor blocker therapy.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  63. AMCOFF K, Stridsberg M, Lampinen M, Magnuson A, et al
    Clinical implications of assay specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  64. LANKARANI KB, Sepehrimanesh M, Seghatoleslami F, Hoseini SE, et al
    Autophagy-related protein 7 level in patients with ulcerative colitis.
    Scand J Gastroenterol. 2016.
    PubMed     Text format    


  65. ZHOU G, Yang W, Yu L, Yu T, et al
    CD99 refers to the activity of inflammatory bowel disease.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  66. HUPPERTZ-HAUSS G, Hoivik ML, Jelsness-Jorgensen LP, Opheim R, et al
    Fatigue in a population-based cohort of patients with inflammatory bowel disease 20 years after diagnosis: The IBSEN study.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  67. ENGLUND H, Liden K K, Lind T, Sundstrom T, et al
    Radiation exposure in patients with inflammatory bowel disease and irritable bowel syndrome in the years 2001-2011.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  68. MOLANDER P, Farkkila M, Kemppainen H, Blomster T, et al
    Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFalpha-blocking agents.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  69. JAKOBSSON GL, Sternegard E, Olen O, Myrelid P, et al
    Validating inflammatory bowel disease (IBD) in the Swedish National Patient Register and the Swedish Quality Register for IBD (SWIBREG).
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    September 2016
  70. HOGBERG C, Karling P, Rutegard J, Lilja M, et al
    Diagnosing colorectal cancer and inflammatory bowel disease in primary care: The usefulness of tests for faecal haemoglobin, faecal calprotectin, anaemia and iron deficiency. A prospective study.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  71. MUTHAS D, Reznichenko A, Balendran CA, Bottcher G, et al
    Neutrophils in Ulcerative Colitis: A review of selected biomarkers and their potential therapeutic implications.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  72. FRIGSTAD SO, Hoivik M, Jahnsen J, Dahl SR, et al
    Vitamin D deficiency in inflammatory bowel disease: Prevalence and predictors in a Norwegian outpatient population.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    August 2016
  73. LEHTOLA E, Haapamaki J, Farkkila MA
    Outcome of inflammatory bowel disease patients treated with TNF-alpha inhibitors: two-year follow-up.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  74. KISZKA-KANOWITZ M, Theede K, Mertz-Nielsen A
    Randomized clinical trial: a pilot study comparing efficacy of low-dose azathioprine and allopurinol to azathioprine on clinical outcomes in inflammatory bowel disease.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  75. PROSBERG M, Bendtsen F, Vind I, Petersen AM, et al
    The association between the gut microbiota and the inflammatory bowel disease activity: a systematic review and meta-analysis.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    July 2016
  76. JANSEN A, Mandic AD, Bennek E, Frehn L, et al
    Anti-food and anti-microbial IgG subclass antibodies in inflammatory bowel disease.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  77. HOLT DQ, Strauss BJ, Lau KK, Moore GT, et al
    Body composition analysis using abdominal scans from routine clinical care in patients with Crohn's Disease.
    Scand J Gastroenterol. 2016;51:842-7.
    PubMed     Text format     Abstract available


    June 2016
  78. RONNBLOM A, Holmstrom T, Tanghoj H, Karlbom U, et al
    Low colectomy rate five years after diagnosis of ulcerative colitis. Results from a prospective population-based cohort in Sweden (ICURE) diagnosed during 2005-2009.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  79. VON VOLKMANN HL, Nylund K, Tronstad RR, Hovdenak N, et al
    An activating gucy2c mutation causes impaired contractility and fluid stagnation in the small bowel.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  80. DAHLERUP JF, Jacobsen BA, van der Woude J, Bark LA, et al
    High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  81. GRIMSTAD T, Norheim KB, Kvaloy JT, Isaksen K, et al
    Conventional treatment regimens for ulcerative colitis alleviate fatigue - an observational cohort study.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    May 2016
  82. ALATRI A, Schoepfer A, Fournier N, Engelberger RP, et al
    Prevalence and risk factors for venous thromboembolic complications in the Swiss Inflammatory Bowel Disease Cohort.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  83. STIO M, Retico L, Annese V, Bonanomi AG, et al
    Vitamin D regulates the tight-junction protein expression in active ulcerative colitis.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  84. FOLLIN-ARBELET B, Moum B
    Fluoride: a risk factor for inflammatory bowel disease?
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  85. LARSEN MD, Baldal ME, Nielsen RG, Nielsen J, et al
    The incidence of Crohn's disease and ulcerative colitis since 1995 in Danish children and adolescents <17 years - based on nationwide registry data.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  86. STEFANSDOTTIR J, Bjerrum JT, Nielsen SD
    Non-infectious HIV-associated colitis as a differential diagnosis to ulcerative colitis.
    Scand J Gastroenterol. 2016.
    PubMed     Text format    


  87. THORN M, Rorsman F, Ronnblom A, Sangfelt P, et al
    Active cytomegalovirus infection diagnosed by real-time PCR in patients with inflammatory bowel disease: a prospective, controlled observational study.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    March 2016
  88. KEIL R, Wasserbauer M, Zadorova Z, Hajer J, et al
    Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  89. NAKANO M, Oka S, Tanaka S, Kunihara S, et al
    Clinical usefulness of transabdominal ultrasonography prior to patency capsule for suspected small-bowel strictures.
    Scand J Gastroenterol. 2016;51:281-7.
    PubMed     Text format     Abstract available


  90. SUNDE ML, Oresland T, Engebreth Faerden A
    Correlation between pouch function and sexual function in patients with IPAA.
    Scand J Gastroenterol. 2016;51:295-303.
    PubMed     Text format     Abstract available


  91. ZHULINA Y, Udumyan R, Tysk C, Montgomery S, et al
    The changing face of Crohn's disease: a population-based study of the natural history of Crohn's disease in Orebro, Sweden 1963-2005.
    Scand J Gastroenterol. 2016;51:304-13.
    PubMed     Text format     Abstract available


    February 2016
  92. KIM JH, Cheon JH, Park Y, Lee HJ, et al
    Effect of mucosal healing (Mayo 0) on clinical relapse in patients with ulcerative colitis in clinical remission.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  93. MORITA Y, Bamba S, Takahashi K, Imaeda H, et al
    Prediction of clinical and endoscopic responses to anti-tumor necrosis factor-alpha antibodies in ulcerative colitis.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  94. VEGH Z, Kurti Z, Gonczi L, Golovics PA, et al
    Association of extraintestinal manifestations and anaemia with disease outcomes in patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  95. THORSEN SU, Jakobsen C, Cohen A, Lundqvist M, et al
    Perinatal vitamin D levels are not associated with later risk of developing pediatric-onset inflammatory bowel disease: a Danish case-cohort study.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  96. TAKAHASHI F, Tominaga K, Kanamori A, Takenaka K, et al
    Timing for dose-down of 5-ASA depends on mucosal status with ulcerative colitis.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    January 2016
  97. NUKI Y, Esaki M, Asano K, Maehata Y, et al
    Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: a single center experience.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  98. REENAERS C, Pirard C, Vankemseke C, Latour P, et al
    Long-term evolution and predictive factors of mild inflammatory bowel disease.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  99. MOUSSATA D, Boschetti G, Stefanescu C, Nancey S, et al
    Isolated ileitis associated with primary sclerosing cholangitis in three patients with Crohn's disease.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  100. HOLDAM AS, Bager P, Dahlerup JF
    Biological therapy increases the health-related quality of life in patients with inflammatory bowel disease in a clinical setting.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  101. ELIGIUS HELLSTROM A, Farkkila M, Kolho KL
    Infliximab-induced skin manifestations in patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  102. FASCI-SPURIO F, Pavlidis P, Bjarnason I
    A new form of chronic inflammatory bowel disease associated with chronic liver disease.
    Scand J Gastroenterol. 2016.
    PubMed     Text format    


  103. SEIDELIN JB
    Regulation of antiapoptotic and cytoprotective pathways in colonic epithelial cells in ulcerative colitis.
    Scand J Gastroenterol. 2016;51.
    PubMed     Text format     Abstract available


  104. MAGRO F, Coelho R, Guimaraes LS, Silva M, et al
    Anti-TNF therapy and radiation exposure in Crohn's disease: chicken or egg?
    Scand J Gastroenterol. 2016;51:511-2.
    PubMed     Text format    


  105. AGGARWAL D, Limdi JK
    Letter to the editor: anti-TNF therapy and radiation exposure in Crohn's disease: chicken or egg?
    Scand J Gastroenterol. 2016;51:507-8.
    PubMed     Text format    


  106. GARCIA-MEDINA JJ, Pastor-Grau A, del-Rio-Vellosillo M, Zanon-Moreno V, et al
    Unilateral and irreversible optic neuropathy associated to infliximab treatment: 3-year follow-up.
    Scand J Gastroenterol. 2016;51:765-6.
    PubMed     Text format    


  107. BAJI P, Gulacsi L, Lovasz BD, Golovics PA, et al
    Treatment preferences of originator versus biosimilar drugs in Crohn's disease; discrete choice experiment among gastroenterologists.
    Scand J Gastroenterol. 2016;51:22-7.
    PubMed     Text format     Abstract available


  108. FERREIRO-IGLESIAS R, Barreiro-de Acosta M, Lorenzo-Gonzalez A, Dominguez-Munoz JE, et al
    Usefulness of a rapid faecal calprotectin test to predict relapse in Crohn's disease patients on maintenance treatment with adalimumab.
    Scand J Gastroenterol. 2016;51:442-7.
    PubMed     Text format     Abstract available


  109. PARK SK, Hong M, Ye BD, Kim KJ, et al
    Influences of XDH genotype by gene-gene interactions with SUCLA2 for thiopurine-induced leukopenia in Korean patients with Crohn's disease.
    Scand J Gastroenterol. 2016;51:684-91.
    PubMed     Text format     Abstract available


  110. DIGE A, Magnusson MK, Ohman L, Hvas CL, et al
    Reduced numbers of mucosal DR(int) macrophages and increased numbers of CD103(+) dendritic cells during anti-TNF-alpha treatment in patients with Crohn's disease.
    Scand J Gastroenterol. 2016;51:692-9.
    PubMed     Text format     Abstract available


  111. GABRYEL M, Skrzypczak-Zielinska M, Kucharski MA, Slomski R, et al
    The impact of genetic factors on response to glucocorticoids therapy in IBD.
    Scand J Gastroenterol. 2016;51:654-65.
    PubMed     Text format     Abstract available


  112. HERRANZ BACHILLER MT, Barrio Andres J, Fernandez Salazar L, Ruiz-Zorrilla R, et al
    The utility of faecal calprotectin to predict post-operative recurrence in Crohns disease.
    Scand J Gastroenterol. 2016;51:720-6.
    PubMed     Text format     Abstract available


  113. COELHO R, Magro F, Silva M, Macedo G, et al
    Early surgery in Crohn's disease patients with entero-urinary fistulas: does it change the prognosis?
    Scand J Gastroenterol. 2016;51:679-83.
    PubMed     Text format     Abstract available


    December 2015
  114. JELSNESS-JORGENSEN LP, Bernklev T, Hovde O, Prytz Berset I, et al
    Patients' perceptions of quality of care and follow-up in inflammatory bowel disease.
    Scand J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  115. KRISTENSEN V, Malmstrom GH, Skar V, Roseth A, et al
    Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure.
    Scand J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


    November 2015
  116. AHMED I, Fayyaz F, Nasir M, Niaz Z, et al
    Extending landscape of volatile metabolites as novel diagnostic biomarkers of inflammatory bowel disease - a review.
    Scand J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


    October 2015
  117. KORAL ONAL I, Alizadeh N, Gok Sargin Z
    Performance of interferon-gamma release assay for tuberculosis screening in inflammatory bowel disease patients: Disease activity as an influencing factor.
    Scand J Gastroenterol. 2015.
    PubMed     Text format    


  118. MANTZARIS GJ, Papamichael K
    Author's reply to performance of interferon-gamma release assay for tuberculosis screening in inflammatory bowel disease patients: disease activity as an influencing factor.
    Scand J Gastroenterol. 2015.
    PubMed     Text format    


    September 2015
  119. MIRSEPASI-LAURIDSEN HC, Bachmann Holmetoft U, Ingdam Halkjaer S, Angeliki Krogfelt K, et al
    Comparison of three commercial fecal calprotectin ELISA test kits used in patients with Inflammatory Bowel Disease.
    Scand J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  120. BORTLIK M, Duricova D, Machkova N, Hruba V, et al
    Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
    Scand J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


    August 2015
  121. PRINCIPI M, Scavo MP, Piscitelli D, Villanacci V, et al
    The sharp decline of beta estrogen receptors expression in long-lasting ulcerative-associated carcinoma.
    Scand J Gastroenterol. 2015;50:1002-10.
    PubMed     Text format     Abstract available


    July 2015
  122. PRINCIPI M, Montenegro L, Losurdo G, Zito A, et al
    Endothelial function and cardiovascular risk in patients with inflammatory bowel disease in remission phase.
    Scand J Gastroenterol. 2015.
    PubMed     Text format    


  123. FERNANDEZ-SALAZAR L, Munoz F, Barrio J, Munoz C, et al
    Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study).
    Scand J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  124. GUINET-CHARPENTIER C, Champigneulle J, Williet N, Peyrin-Biroulet L, et al
    The association of autoimmune diseases with pediatric ulcerative colitis does not influence its disease course.
    Scand J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  125. SOLBERG IC, Hoivik ML, Cvancarova M, Moum B, et al
    Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study).
    Scand J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  126. MANTZARIS GJ, Tsironikos D, Tzanetakou X, Grispou E, et al
    The impact of immunosuppressive therapy on QuantiFERON and tuberculin skin test for screening of latent tuberculosis in patients with inflammatory bowel disease scheduled for anti-TNF therapy.
    Scand J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  127. CLEMMENSEN K, Akrawi N, Stawowy M
    Irreversible optic neuritis after infliximab treatment in a patient with ulcerative colitis.
    Scand J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  128. GECSE KB, Brandse JF, van Wilpe S, Lowenberg M, et al
    Impact of disease location on fecal calprotectin levels in Crohn's disease.
    Scand J Gastroenterol. 2015;50:841-7.
    PubMed     Text format     Abstract available


    June 2015
  129. LIU G, Lin J, Xie H, Shen B, et al
    Histomorphological features and prognosis of colitis-associated colorectal cancer in patients with primary sclerosing cholangitis.
    Scand J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


    May 2015
  130. BJORNSSON S, Tryggvason FThorn, Jonasson JG, Cariglia N, et al
    Incidence of inflammatory bowel disease in Iceland 1995 - 2009. A nationwide population-based study.
    Scand J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  131. BRENNA O, Bruland T, Furnes MW, Granlund AV, et al
    The guanylate cyclase-C signaling pathway is down-regulated in inflammatory bowel disease.
    Scand J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  132. VOGELAAR L, van den Berg-Emons R, Bussmann H, Rozenberg R, et al
    Physical fitness and physical activity in fatigued and non-fatigued inflammatory bowel disease patients.
    Scand J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  133. CAVIGLIA GP, Pellicano R, Astegiano M
    Reply to: Diagnostic power of fecal calprotectin in inflammatory and functional intestinal disorders.
    Scand J Gastroenterol. 2015;50:623-4.
    PubMed     Text format    


    March 2015
  134. AGILLI M, Aydin FN, Gulcan Kurt Y, Cayci T, et al
    Diagnostic power of fecal calprotectin in inflammatory and functional intestinal disorders.
    Scand J Gastroenterol. 2015;50:376-7.
    PubMed     Text format    


  135. VEGH Z, Golovics PA, Lovasz BD, Kurti Z, et al
    Low incidence of venous thromboembolism in inflammatory bowel diseases: prevalence and predictors from a population-based inception cohort.
    Scand J Gastroenterol. 2015;50:306-11.
    PubMed     Text format     Abstract available


    February 2015
  136. BOR R, Farkas K, Balint A, Szucs M, et al
    Efficacy of combined anti-TNF-alpha and surgical therapy in perianal and enterocutaneous fistulizing Crohn's disease--clinical observations from a tertiary Eastern European center.
    Scand J Gastroenterol. 2015;50:182-7.
    PubMed     Text format     Abstract available


    January 2015
  137. ORESLAND T, Faerden AE
    Surgery in the age of biological treatment.
    Scand J Gastroenterol. 2015;50:121-7.
    PubMed     Text format     Abstract available


  138. RIMOLA J, Panes J, Ordas I
    Magnetic resonance enterography in Crohn's disease: optimal use in clinical practice and clinical trials.
    Scand J Gastroenterol. 2015;50:66-73.
    PubMed     Text format     Abstract available


  139. LATELLA G, Di Gregorio J, Flati V, Rieder F, et al
    Mechanisms of initiation and progression of intestinal fibrosis in IBD.
    Scand J Gastroenterol. 2015;50:53-65.
    PubMed     Text format     Abstract available


  140. NAKAMURA S, Sho M, Koyama F, Ueda T, et al
    Erythropoietin attenuates intestinal inflammation and promotes tissue regeneration.
    Scand J Gastroenterol. 2015;50:1094-102.
    PubMed     Text format     Abstract available


    November 2014
  141. CAVIGLIA GP, Pantaleoni S, Touscoz GA, Adriani A, et al
    Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders.
    Scand J Gastroenterol. 2014.
    PubMed     Text format     Abstract available


    September 2014
  142. HOOG CM, Bark LA, Brostrom O, Sjoqvist U, et al
    Capsule endoscopic findings correlate with fecal calprotectin and C-reactive protein in patients with suspected small-bowel Crohn's disease.
    Scand J Gastroenterol. 2014;49:1084-90.
    PubMed     Text format     Abstract available


    August 2014
  143. JULSGAARD M, Norgaard M, Hvas CL, Grosen A, et al
    Self-reported adherence to medical treatment, breastfeeding behaviour, and disease activity during the postpartum period in women with Crohn's disease.
    Scand J Gastroenterol. 2014;49:958-66.
    PubMed     Text format     Abstract available


  144. IDESTROM M, Rubio CA, Onelov E, Henter JI, et al
    Pediatric Crohn's disease from onset to adulthood: granulomas are associated with an early need for immunomodulation.
    Scand J Gastroenterol. 2014;49:950-7.
    PubMed     Text format     Abstract available


    July 2014
  145. TABIBIAN JH, O'Hara SP, Lindor KD
    Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies.
    Scand J Gastroenterol. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: